UBS Asset Management Americas Inc. Sells 4,500 Shares of NuCana PLC (NASDAQ:NCNA)

Share on StockTwits

UBS Asset Management Americas Inc. lessened its position in NuCana PLC (NASDAQ:NCNA) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 183,000 shares of the company’s stock after selling 4,500 shares during the period. UBS Asset Management Americas Inc. owned 0.57% of NuCana worth $1,900,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NCNA. Marshall Wace North America L.P. boosted its stake in shares of NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after purchasing an additional 51,607 shares in the last quarter. Rothschild Investment Corp IL boosted its stake in shares of NuCana by 126.1% during the 2nd quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock valued at $291,000 after purchasing an additional 15,660 shares in the last quarter. Aperio Group LLC bought a new stake in shares of NuCana during the 2nd quarter valued at about $39,000. Asymmetry Capital Management L.P. boosted its stake in shares of NuCana by 257.8% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 162,414 shares of the company’s stock valued at $1,686,000 after purchasing an additional 117,021 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of NuCana by 134,310.2% during the 2nd quarter. BlackRock Inc. now owns 608,878 shares of the company’s stock valued at $6,320,000 after purchasing an additional 608,425 shares in the last quarter. 36.07% of the stock is currently owned by institutional investors and hedge funds.

NCNA opened at $6.15 on Friday. The firm has a 50 day moving average price of $8.04 and a 200-day moving average price of $11.24. NuCana PLC has a twelve month low of $4.01 and a twelve month high of $21.48.

NuCana (NASDAQ:NCNA) last released its quarterly earnings data on Wednesday, August 21st. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. As a group, research analysts predict that NuCana PLC will post -0.94 EPS for the current fiscal year.

NCNA has been the topic of a number of research reports. ValuEngine raised shares of NuCana from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. William Blair reissued a “buy” rating on shares of NuCana in a research note on Thursday, September 5th. Citigroup set a $25.00 price objective on shares of NuCana and gave the stock a “buy” rating in a research note on Wednesday, August 21st. Piper Jaffray Companies reissued an “overweight” rating and set a $25.00 price objective (down previously from $35.00) on shares of NuCana in a research note on Friday, August 23rd. Finally, Zacks Investment Research raised shares of NuCana from a “hold” rating to a “strong-buy” rating and set a $8.75 price objective on the stock in a research note on Saturday, August 24th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.69.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Featured Story: Does the discount rate affect the economy?

Want to see what other hedge funds are holding NCNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuCana PLC (NASDAQ:NCNA).

Institutional Ownership by Quarter for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Vanguard Group Inc. Boosts Holdings in Adient PLC
Vanguard Group Inc. Boosts Holdings in Adient PLC
UBS Asset Management Americas Inc. Sells 4,500 Shares of NuCana PLC
UBS Asset Management Americas Inc. Sells 4,500 Shares of NuCana PLC
UBS Asset Management Americas Inc. Acquires 959 Shares of LCI Industries
UBS Asset Management Americas Inc. Acquires 959 Shares of LCI Industries
Cannae Holdings Inc  Shares Purchased by UBS Asset Management Americas Inc.
Cannae Holdings Inc Shares Purchased by UBS Asset Management Americas Inc.
Capital Investment Services of America Inc. Lowers Stock Holdings in Alphabet Inc
Capital Investment Services of America Inc. Lowers Stock Holdings in Alphabet Inc
Fuel Tech Inc  Given Average Rating of “Strong Buy” by Brokerages
Fuel Tech Inc Given Average Rating of “Strong Buy” by Brokerages


© 2006-2019 Ticker Report